Paclitaxel AqVida IV Infusion 6 mg/ml Introduction
Paclitaxel AqVida IV Infusion 6 mg/ml is a chemotherapy drug used to treat various types of cancer, including ovarian, cervical, and other types of cancer. It works by interfering with the growth of cancerous cells. It is usually given intravenously (through a vein) into a vein in the arm or chest, and can be given as an injection.
Uses for Paclitaxel AqVida IV Infusion 6 mg/ml
Paclitaxel AqVida IV Infusion 6 mg/ml is used to treat various types of cancer, including ovarian, cervical, and other types of cancer. It is often used in combination with other medications to improve its effectiveness. It can be used to reduce the size of a tumor or to shrink a tumor before surgery. In some cases, it can also be given to relieve symptoms such as pain, fatigue, or difficulty breathing.
| Brand Name | Paclitaxel AqVida |
|---|---|
| Type | IV Infusion |
| Weight | 6 mg/ml |
| Generic | Paclitaxel |
| Manufacturer | BioRx |
| Available in | English বাংলা |
Mechanism of Action
Paclitaxel AqVida IV Infusion 6 mg/ml works by preventing the growth of cancer cells. It does this by interfering with the ability of cancer cells to divide and multiply. This makes it harder for cancer cells to spread to other parts of the body. It also interferes with the ability of cancer cells to repair themselves, making it harder for them to survive.
How Long Does it Take to Work?
Paclitaxel AqVida IV Infusion 6 mg/ml typically takes between 2 and 4 weeks to begin to work. During this time, it will work to slow the growth of cancer cells. In some cases, it may take up to 6 weeks before its effects can be seen.
Absorption
Paclitaxel AqVida IV Infusion 6 mg/ml is generally absorbed very well when given intravenously. Its rate of absorption may be affected by certain medications or other factors.
Route of Elimination
Paclitaxel AqVida IV Infusion 6 mg/ml is eliminated primarily through the kidneys in the form of metabolites. It is excreted in the urine.
Dosage
All patients should be premedicated prior to Paclitaxel administration in order to prevent severe hypersensitivity reactions. Such premedication may consist of dexamethasone 20 mg PO administered approximately 12 and 6 hours before Paclitaxel, diphenhydramine (or its equivalent) 50 mg IV 30 to 60 minutes prior to Paclitaxel, and cimetidine (300 mg) or ranitidine (50 mg) IV 30 to 60 minutes before Paclitaxel.First-line treatment of ovarian cancer: Although alternative medication regimens for paclitaxel are under investigation at present, a combination therapy of paclitaxel and cisplatin is recommended. Depending on the duration of infusion, two different dosages are recommended for paclitaxel treatment: 175 mg/m2 of paclitaxel is administered as an intravenous infusion over a period of three hours followed thereafter by 75 mg/m2 of cisplatin and the therapy is repeated at 3-week intervals, or 135 mg/m2 of paclitaxel is administered as an intravenous infusion over a period of 24 hours followed thereafter by 75 mg/m2 of cisplatin and the therapy is repeated at 3-week intervals.
Second-line treatment of ovarian cancer: The recommended dose of paclitaxel is 175 mg/m2 administered over 3 hours, with a 3-week interval between courses.
Adjuvant chemotherapy in breast carcinoma: The recommended dose of paclitaxel is 175 mg/m2 administered over a period of 3 hours every 3 weeks for four courses, following AC therapy.
First-line chemotherapy of breast carcinoma: When used in combination with doxorubicin (50 mg/m2), paclitaxel should be administered 24 hours after doxorubicin. The recommended dose of paclitaxel is 220 mg/m2 administered intravenously over a period of 3 hours, with a 3-week interval between courses. When used in combination with trastuzumab, the recommended dose of paclitaxel is 175 mg/m2 administered intravenously over a period of 3 hours, with a 3-week interval between courses. Paclitaxel infusion may be started the day following the first dose of trastuzumab or immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated.
Second-line chemotherapy of breast carcinoma: The recommended dose of paclitaxel is 175 mg/m2 administered over a period of 3 hours, with a 3-week interval between courses.
Advanced non-small-cell lung cancer: The recommended dose of paclitaxel is 175 mg/m2 administered over 3 hours followed by 80 mg/m2 of cisplatin, with a 3-week interval between courses.
Treatment of AIDS-related KS: The recommended dose of paclitaxel is 100 mg/m2 administered as a 3-hour intravenous infusion every two weeks.
Dose adjustment: Subsequent doses of paclitaxel should be administered according to individual patient tolerance. Paclitaxel should not be re-administered until the neutrophil count is >1.5 x 109/1 (>1 x 109/1 for KS patients) and the platelet count is >100 x 109/1 (>75 x 109/1 for KS patients).
The recommended dosage of Paclitaxel AqVida IV Infusion 6 mg/ml depends on the type and stage of the cancer being treated. The dose may be adjusted based on the individual's body weight, kidney and liver function, and other factors. For more detailed information on dosage, it is important to consult a doctor.
Administration
Paclitaxel AqVida IV Infusion 6 mg/ml is typically administered intravenously (through a vein) in a hospital or clinic. It is important to follow the doctor's instructions for proper administration.
Side Effects
Common side effects of Paclitaxel AqVida IV Infusion 6 mg/ml include hair loss, nausea, vomiting,loss of appetite, fatigue, constipation, diarrhea, and mouth sores. Other side effects include skin rash, dizziness, and bone marrow suppression. In rare cases, it may cause serious side effects such as low blood cell count, allergic reactions, or liver damage.
Toxicity
High doses of Paclitaxel AqVida IV Infusion 6 mg/ml can cause serious toxicity, including kidney and liver damage, bone marrow suppression, and nerve damage. It is important to follow the doctor's instructions carefully to minimize the risk of serious side effects.
Precautions
It is important to tell the doctor about any health conditions, including allergies, prior to taking Paclitaxel AqVida IV Infusion 6 mg/ml. Women should also tell the doctor if they are pregnant or are planning to become pregnant, as Paclitaxel AqVida IV Infusion 6 mg/ml may cause harm to the unborn baby. It is also important to tell the doctor if breastfeeding, as Paclitaxel AqVida IV Infusion 6 mg/ml can pass into breast milk.
Interaction
Paclitaxel AqVida IV Infusion 6 mg/ml should not be taken with certain other medications, as it can interact with them and cause serious side effects. It is important to tell the doctor about all medications being taken, including prescription, over-the-counter, herbal supplements, and vitamins.
Disease Interaction
Paclitaxel AqVida IV Infusion 6 mg/ml should not be taken by people with certain diseases, such as liver or kidney disease. It is important to tell the doctor about any existing diseases before taking Paclitaxel AqVida IV Infusion 6 mg/ml.
Drug Interactions
It is important to tell the doctor about any other medications being taken, including prescription, over-the-counter, herbal supplements, and vitamins, as Paclitaxel AqVida IV Infusion 6 mg/ml can interact with certain medications and cause serious side effects.
Food Interactions
Certain foods should be avoided when taking Paclitaxel AqVida IV Infusion 6 mg/ml, as they may interact with the drug and cause serious side effects. It is important to consult the doctor about what to eat during treatment.
Pregnancy Use
Paclitaxel AqVida IV Infusion 6 mg/ml should not be taken during pregnancy, as it can harm the unborn baby. Women should tell the doctor if they are pregnant or are planning to become pregnant before taking Paclitaxel AqVida IV Infusion 6 mg/ml.
Lactation Use
It is not known if Paclitaxel AqVida IV Infusion 6 mg/ml is safe to use while breastfeeding. Women should discuss the potential risks with their doctor before taking this medication while breastfeeding.
Acute Overdose
Symptoms of an overdose may include headache, drowsiness, nausea, vomiting, diarrhea, and abdominal pain. If an overdose is suspected, it is important to seek emergency medical treatment right away.
Contraindication
Paclitaxel AqVida IV Infusion 6 mg/ml should not be used by people with certain conditions, including liver or kidney disease. It should also not be used by people who are allergic to Paclitaxel AqVida IV Infusion 6 mg/ml or any of its ingredients.
Use Direction
Paclitaxel AqVida IV Infusion 6 mg/ml should be used as directed by the doctor. It is important to follow the instructions carefully to get the most benefit from the medication. The medication should be taken at the same time each day, with or without food.
Storage Condition
Paclitaxel AqVida IV Infusion 6 mg/ml should be stored at room temperature, away from direct sunlight, and out of the reach of children. It should not be kept in the bathroom or near a sink.
Volume of Distribution
The volume of distribution of Paclitaxel AqVida IV Infusion 6 mg/ml is approximately 18 liters. This means that any given dose of the medication is distributed throughout the body in a volume of 18 liters.
Half Life
The half life of Paclitaxel AqVida IV Infusion 6 mg/ml is approximately 4 to 5 hours. This means that half of any given dose of Paclitaxel AqVida IV Infusion 6 mg/ml will remain in the body for approximately 4 to 5 hours.
Clearance
The clearance of Paclitaxel AqVida IV Infusion 6 mg/ml is approximately 27 mL/min per 1.73 m^2. This means that any given dose of the medication is eliminated from the body at a rate of 27 mL/min per 1.73 m^2.
See in details version Paclitaxel AqVida IV Infusion 6 mg/ml also Paclitaxel AqVida IV Infusion 6 mg/ml in bangla
Some Frequently Asked Questions About Paclitaxel AqVida IV Infusion 6 mg/ml
